Deucrictibant (PHA-022121), ICATIBANT , Placebo matches Deucritibant soft capsules with exception of active substance. clinical trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Attacks in Adolescents and Adults with Hereditary Angioedema.

This study is testing a new soft capsule medicine for people with Hereditary Angioedema (HAE) to quickly stop attacks. It compares the new medicine, called deucrictibant, with a dummy capsule (placebo) and another existing medicine to see how fast it relieves symptoms.